[go: up one dir, main page]

BRPI0607326B8 - composição de vacina, uso da referida composição e kit em partes - Google Patents

composição de vacina, uso da referida composição e kit em partes

Info

Publication number
BRPI0607326B8
BRPI0607326B8 BRPI0607326A BRPI0607326A BRPI0607326B8 BR PI0607326 B8 BRPI0607326 B8 BR PI0607326B8 BR PI0607326 A BRPI0607326 A BR PI0607326A BR PI0607326 A BRPI0607326 A BR PI0607326A BR PI0607326 B8 BRPI0607326 B8 BR PI0607326B8
Authority
BR
Brazil
Prior art keywords
composition
vaccine
kit
parts
vaccine composition
Prior art date
Application number
BRPI0607326A
Other languages
English (en)
Inventor
Hald Andersen Mads
Original Assignee
Survac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Survac Aps filed Critical Survac Aps
Publication of BRPI0607326A2 publication Critical patent/BRPI0607326A2/pt
Publication of BRPI0607326B1 publication Critical patent/BRPI0607326B1/pt
Publication of BRPI0607326B8 publication Critical patent/BRPI0607326B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composição de vacina, variante de peptídeo de survivina, uso da referida composição, kit em partes e medicamento. a presente invenção refere-se a uma vacina terapêutica compreendendo um ou mais fragmentos de polipeptídeo de survivina. a vacina pode ser usada para o tratamento profilático, de melhora e/ou curativo de, por exemplo, doenças de câncer. a invenção refere-se ainda a métodos de tratamento de combinação.
BRPI0607326A 2005-02-04 2006-02-03 composição de vacina, uso da referida composição e kit em partes BRPI0607326B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500173 2005-02-04
DKPA200500173 2005-02-04
US65075105P 2005-02-07 2005-02-07
US60/650,751 2005-02-07
PCT/DK2006/000061 WO2006081826A2 (en) 2005-02-04 2006-02-03 Survivin peptide vaccine

Publications (3)

Publication Number Publication Date
BRPI0607326A2 BRPI0607326A2 (pt) 2009-09-01
BRPI0607326B1 BRPI0607326B1 (pt) 2021-01-19
BRPI0607326B8 true BRPI0607326B8 (pt) 2021-05-25

Family

ID=39042995

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607326A BRPI0607326B8 (pt) 2005-02-04 2006-02-03 composição de vacina, uso da referida composição e kit em partes

Country Status (15)

Country Link
US (1) US20110091489A1 (pt)
EP (3) EP2329840A1 (pt)
JP (2) JP2008528643A (pt)
KR (1) KR20070108536A (pt)
CN (3) CN101111260B (pt)
AU (1) AU2006209951B2 (pt)
BR (1) BRPI0607326B8 (pt)
CA (1) CA2593714C (pt)
DK (1) DK1853305T3 (pt)
ES (1) ES2523172T3 (pt)
MX (1) MX2007009219A (pt)
PL (1) PL1853305T3 (pt)
RU (1) RU2396088C2 (pt)
WO (1) WO2006081826A2 (pt)
ZA (1) ZA200705943B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3620465B1 (en) * 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2009106073A2 (en) * 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
PT2280721T (pt) 2008-04-17 2018-02-16 Io Biotech Aps Imunoterapia à base de indoleamina 2,3-dioxigenase
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
FR2955775B1 (fr) 2010-02-01 2012-05-04 Seppic Sa Adjuvant pour la preparation de compositions vaccinales destinees a la prevention contre les coccidioses
FR2955776A1 (fr) * 2010-02-01 2011-08-05 Seppic Sa Utilisation d'une huile minerale specifique pour la fabrication d'un nouveau adjuvant
EP3912634B1 (en) 2012-05-16 2023-10-04 Stemline Therapeutics Inc. Cancer stem cell targeted cancer vaccines
ES2886999T3 (es) * 2013-03-27 2021-12-21 Immunovaccine Technologies Inc Procedimiento para mejorar la eficacia de una vacuna de survivina en el tratamiento de cáncer
WO2015090572A1 (en) * 2013-12-16 2015-06-25 Merck Patent Gmbh Survivin-directed cancer vaccine therapy
HK1245280A1 (zh) 2015-01-06 2018-08-24 Immunovaccine Technologies Inc. 脂质a模拟物、其制备方法和用途
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
CA3005127C (en) 2015-11-18 2023-01-24 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
WO2017147263A1 (en) * 2016-02-23 2017-08-31 National Health Research Institutes Lipidated survivin and the use thereof for prevention and treatment of cancers
AU2017234192B2 (en) 2016-03-16 2024-04-04 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
KR102879364B1 (ko) 2016-09-21 2025-11-04 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
CN107228894B (zh) * 2017-01-24 2019-03-19 浙江海隆生物科技有限公司 一种油乳剂蛋白亚单位疫苗中蛋白含量和纯度的检测方法及其应用
MA47677A (fr) 2017-03-03 2020-01-08 Treos Bio Zrt Vaccins peptidiques
JP6993677B2 (ja) * 2017-11-08 2022-01-13 学校法人日本医科大学 犬におけるがんの予防、がんの治療またはがんの転移の予防のためのがんペプチドワクチン
WO2019133853A1 (en) * 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
SG11202101888YA (en) 2018-09-04 2021-03-30 Treos Bio Ltd Peptide vaccines
WO2020104923A1 (en) * 2018-11-19 2020-05-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
CN115477686B (zh) * 2022-09-22 2024-01-30 北海黑珍珠海洋生物科技有限公司 一种具有美白功效的珍珠贝活性肽及其应用
WO2024186623A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making dried pharmaceutical compositions
WO2024186646A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making lipid adjuvanted compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU679902B2 (en) * 1992-09-30 1997-07-17 Ohio State University Research Foundation, The Vaccines and antigenic conjugates
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6245523B1 (en) 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
WO2002000892A1 (en) * 2000-06-26 2002-01-03 Glaxosmithkline Biologicals S.A. Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
DK1333850T3 (da) * 2000-10-20 2008-12-01 Genetics Inst Anvendelse af IL-13-inhibitorer til behandling af tumorer
JP2002365286A (ja) * 2000-11-13 2002-12-18 Kyogo Ito 細胞性免疫検出法およびその医薬への応用
JP4780540B2 (ja) * 2001-03-23 2011-09-28 北海道公立大学法人 札幌医科大学 サバイビン由来癌抗原ペプチド
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6780121B2 (en) * 2002-09-09 2004-08-24 Paul J. Herber Golf club head construction
US7342092B2 (en) * 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
US7221826B2 (en) * 2002-10-08 2007-05-22 Tdk Corporation Spot-size transformer, method of producing spot-size transformer and waveguide-embedded optical circuit using spot-size transformer
ES2323692T3 (es) * 2002-12-02 2009-07-23 Resistentia Holding Ab Metodos y materiales para tratar afecciones inflamatorias usando un polipeptido que comprende un segmento de aminoacidos c5 autogenicos y un segmento de aminoacidos no autogenicos.
EP2154145B1 (en) * 2003-01-15 2013-04-24 International Institute of Cancer Immunology, Inc. Dimerized peptide
ES2478446T3 (es) * 2003-06-27 2014-07-22 International Institute Of Cancer Immunology, Inc. Método de selección de pacientes candidatos para la vacuna contra WT1
ES2436429T3 (es) * 2003-11-19 2014-01-02 Survac Aps Uso terapéutico de péptidos derivados de la proteína Bcl-XL en pacientes con cáncer

Also Published As

Publication number Publication date
JP2008528643A (ja) 2008-07-31
BRPI0607326B1 (pt) 2021-01-19
EP2329841A1 (en) 2011-06-08
US20110091489A1 (en) 2011-04-21
MX2007009219A (es) 2008-01-16
ES2523172T3 (es) 2014-11-21
CA2593714C (en) 2013-09-10
HK1112367A1 (en) 2008-08-29
JP2012149101A (ja) 2012-08-09
BRPI0607326A2 (pt) 2009-09-01
EP1853305A2 (en) 2007-11-14
EP2329840A1 (en) 2011-06-08
JP5631357B2 (ja) 2014-11-26
EP1853305B1 (en) 2014-08-20
WO2006081826A2 (en) 2006-08-10
DK1853305T3 (en) 2014-12-01
AU2006209951A1 (en) 2006-08-10
CN103143004A (zh) 2013-06-12
KR20070108536A (ko) 2007-11-12
CN101111260A (zh) 2008-01-23
AU2006209951B2 (en) 2011-04-14
CN103169958A (zh) 2013-06-26
ZA200705943B (en) 2008-12-31
CA2593714A1 (en) 2006-08-10
RU2007133103A (ru) 2009-03-10
CN101111260B (zh) 2013-03-20
RU2396088C2 (ru) 2010-08-10
WO2006081826A3 (en) 2007-02-15
PL1853305T3 (pl) 2015-02-27

Similar Documents

Publication Publication Date Title
BRPI0607326B8 (pt) composição de vacina, uso da referida composição e kit em partes
BR112019000598A2 (pt) rna para terapia de câncer
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
CR9348A (es) Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer
BRPI0415304A (pt) métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou variante bioativos, e de uma composição imunogênica
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BR112012018947B1 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
PA8639701A1 (es) Composicion del anticuerpo her2
ME01133B (me) Kombinovana terapija sa peptidnim epoksiketonima
BR112014009526B8 (pt) Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer
BR112012012918A8 (pt) Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
BRPI0410503B8 (pt) composição tópica e uso da composição
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
CR9994A (es) Vacuna terapéutica
NI201000046A (es) Anticuerpos específicos para la forma de protofibrillas de la proteína beta-amiloide.
BRPI1011236A2 (pt) métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1)
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
BRPI0415315A (pt) métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou derivado bioativos, e de uma composição imunogênica
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF